{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:45:58Z","timestamp":1789019158588,"version":"build-2803163510"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Autoantibodies to the 75-kDa and 100-kDa subunits of the PM\/Scl nucleolar protein complex are associated with an overlap syndrome, manifesting with clinical features of systemic sclerosis and idiopathic inflammatory myopathy. We describe the diverse clinical features in a series of 4 cases with anti-PM\/Scl-75 and\/or anti-PM\/Scl-100 antibodies, including severe proximal muscle weakness, oesophageal dysfunction, respiratory weakness requiring mechanical ventilation, Raynaud\u2019s, calcinosis cutis, sclerodactyly and critical digital ischaemia. Despite the severity of striated and oesophageal muscle weakness, all patients responded very well to immune suppression, and calcinosis cutis in one case regressed substantially. We highlight the efficacy of Rituximab and intravenous immunoglobulin therapy (IVIg) in these cases, enabling return to normal muscle function within six months. Rituximab was preferentially chosen for cases with hyper-gammaglobulinemia and multiple autoantibodies in addition to anti-PM\/Scl, and IVIg was utilised for cases where a rapid onset of effect was required, such as severe ventilator-dependent respiratory muscle weakness and oesophageal dysfunction.<\/jats:p>","DOI":"10.1007\/s00296-021-05075-z","type":"journal-article","created":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T14:02:48Z","timestamp":1641823368000},"page":"359-364","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Rituximab and intravenous immunoglobulin treatment in PM\/Scl antibody-associated disease: case-based review"],"prefix":"10.1007","volume":"42","author":[{"given":"Denesh","family":"Srikantharajah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8091-2717","authenticated-orcid":false,"given":"Patrick D. W.","family":"Kiely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,10]]},"reference":[{"key":"5075_CR1","doi-asserted-by":"publisher","first-page":"e2068","DOI":"10.1212\/WNL.0000000000005638","volume":"90","author":"R De Lorenzo","year":"2018","unstructured":"De Lorenzo R, Pinal-Fernandez I, Huang W, Albayda J, Tiniakou E, Johnson C et al (2018) Muscular and extramuscular clinical features of patients with anti-PM\/Scl autoantibodies. Neurology 90:e2068\u2013e2076","journal-title":"Neurology"},{"key":"5075_CR2","first-page":"1729","volume":"23","author":"W Schnitz","year":"1996","unstructured":"Schnitz W, Taylor-Albert E, Targoff IN, Reichlin M, Scofield RH (1996) Anti-PM\/Scl autoantibodies in patients without clinical polymyositis or scleroderma. J Rheumatol 23:1729\u20131733","journal-title":"J Rheumatol"},{"key":"5075_CR3","first-page":"129","volume":"24","author":"F Vandergheynst","year":"2006","unstructured":"Vandergheynst F, Ocmant A, Sordet C, Humbel RL, Goetz J, Roufosse F et al (2006) Anti-PM\/Scl antibodies in connective tissue disease: clinical and biological assessment of 14 patients. Clin Exp Rheumatol 24:129\u2013133","journal-title":"Clin Exp Rheumatol"},{"key":"5075_CR4","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1002\/art.1780330508","volume":"33","author":"E Genth","year":"1990","unstructured":"Genth E, Mierau R, Genetzky P, von Muhlen CA, Kaufmann S, von Wilmowsky H et al (1990) Immunogenetic associations of scleroderma-related antinuclear antibodies. Arthritis Rheum 33:657\u2013665","journal-title":"Arthritis Rheum"},{"key":"5075_CR5","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.semarthrit.2014.07.002","volume":"44","author":"A Guillen-Del Castillo","year":"2014","unstructured":"Guillen-Del Castillo A, Pilar Sime\u00f3n-Aznar C, Fonollosa-Pla V, Alonso-Vila S, Reverte-Vinaixa MM, Munoz X et al (2014) Good outcome of interstitial lung disease in patients with scleroderma associated to anti-PM\/Scl antibody. Semin Arthritis Rheum 44:331\u2013337","journal-title":"Semin Arthritis Rheum"},{"key":"5075_CR6","doi-asserted-by":"publisher","first-page":"R22","DOI":"10.1186\/ar2614","volume":"11","author":"K Hanke","year":"2009","unstructured":"Hanke K, Br\u00fcckner CS, D\u00e4hnrich C, Huscher D, Komorowski L, Meyer W et al (2009) Antibodies against PM\/Scl-75 and PM\/Scl-100 are independent markers for different subsets of systemic sclerosis patients. Arthritis Res Ther 11:R22","journal-title":"Arthritis Res Ther"},{"key":"5075_CR7","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1136\/annrheumdis-2015-eular.4970","volume":"74","author":"C Bruni","year":"2015","unstructured":"Bruni C, Lages A, Patel H, Harvey J, Ong V, Matucci Cerinic M et al (2015) FRI0459 association of anti-PM\/SCL antibody with risk of malignancy in scleroderma. Ann Rheum Dis 74:593\u2013594","journal-title":"Ann Rheum Dis"},{"key":"5075_CR8","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1093\/rheumatology\/keaa443","volume":"60","author":"M Giannini","year":"2021","unstructured":"Giannini M, Fiorella ML, Tampoia M, Girolamo F, Fornaro M, Amati A et al (2021) Long-term efficacy of adding intravenous immunoglobulins as treatment of refractory dysphagia related to myositis: a retrospective analysis. Rheumatology (Oxford) 60:1234\u20131242","journal-title":"Rheumatology (Oxford)"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-021-05075-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-021-05075-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-021-05075-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T12:07:05Z","timestamp":1643458025000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-021-05075-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,10]]},"references-count":8,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["5075"],"URL":"https:\/\/doi.org\/10.1007\/s00296-021-05075-z","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,10]]},"assertion":[{"value":"28 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}